Semaglutide Real-World Impact: Clinical Results and Budget Implications for Healthcare | Research

The takeaway

Real-world analysis of semaglutide in T2D found significant clinical improvements alongside quantified budget impact, informing healthcare system adoption decisions.

Clinically + economically justified
Real-world semaglutide benefits combined with budget impact analysis show cost justification through prevented diabetes complications

What the researchers found

Real-world semaglutide use produced significant clinical improvements in T2D, with budget impact analysis showing cost justification through prevented complications.

Why it matters

Healthcare budget holders control drug access. Demonstrating that semaglutide's clinical benefits justify its cost through prevented complications supports formulary inclusion and patient access.

The numbers in context

Study period: January 2017 to December 2023. Single tertiary hospital. Patients excluded if they had prior GLP-1 RA use.

How the study worked

Real-world clinical outcomes analysis combined with budget impact modeling for semaglutide in T2D management.

Who was studied

Adults with T2DM initiating semaglutide at a Saudi Arabian tertiary hospital (2017-2023)

What this study cannot tell us

Budget models depend on assumptions. Real-world data has confounders. Cost-effectiveness varies by healthcare system and drug pricing.

How to read the evidence

Moderate evidence: real-world clinical-economic analysis combining outcomes data with budget modeling.

When this study was published

Published in 2025. Provides dual clinical-economic evidence for health system decision-making.

The bigger picture

Healthcare systems globally are evaluating whether expensive GLP-1 drugs are worth the investment. Studies combining clinical and economic evidence provide the data needed for informed coverage decisions.

Questions still open

At what drug price does semaglutide become budget-neutral from prevented complications?
How do different healthcare systems value the real-world benefits differently?
Will biosimilar semaglutide dramatically change the budget calculus?

Common questions

Is semaglutide worth the cost for healthcare systems?

This analysis says yes — when prevented heart attacks, kidney failure, amputations, and other complications are factored in, semaglutide's clinical benefits justify its cost. The key is looking beyond the drug price to the total cost of diabetes care.

Why do insurance companies restrict GLP-1 drugs?

Insurance often focuses on immediate drug costs (,000+/month) without fully accounting for long-term savings from prevented complications. Studies like this help make the case that investing in effective drugs saves money overall.

Read the original research

Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.

Frontiers in clinical diabetes and healthcare, 6, 1677695

View on PubMed ↗Publisher’s paper ↗

Citation

Al-Abdulkarim, Hana A; Alqahtani, Nawaf Salih; Al-Shraim, Mohammad; Almohammed, Omar A. (2025). Real-world clinical and budget impact of semaglutide in type 2 diabetes mellitus in tertiary hospital in Saudi Arabia.. Frontiers in clinical diabetes and healthcare, 6, 1677695. https://doi.org/10.3389/fcdhc.2025.1677695